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Abstract 54 
Background: Early smallpox and Bacillus Calmette-Guérin (BCG) vaccinations have been 55 
associated with reduced risk of cutaneous malignant melanoma (CMM). We assessed the 56 
association between pre-school smallpox vaccination and early-school BCG vaccination and 57 
CMM in a young Danish population. 58 
Methods: We conducted a register-based case-cohort study of individuals growing up during the 59 
phase-out period of smallpox and BCG vaccination in Denmark (born 1965-1976) utilising the 60 
decrease in vaccination during this period. Information on childhood vaccinations and potential 61 
confounders from Copenhagen school health records were linked with nationwide registers on 62 
cancer (CMM diagnoses), migrations and deaths by personal identification numbers. 63 
Results: The individuals were followed from age 18 until 31/12/2014 (maximum age at end of 64 
follow-up, 49 years). 188 cases of CMM occurred in the background population of 46,239 65 
individuals; 172 CMM cases (91%) had full information and were analysed. The adjusted hazard 66 
ratio (HR) for CMM by BCG and/or smallpox vaccination compared with neither vaccine was 67 
1.29 (95% confidence interval (CI) 0.72-2.31). For smallpox vaccination only, HR = 1.23 (95% 68 
CI 0.53-2.86) for BCG vaccination only, HR = 1.13 (95% CI 0.61-2.09) and for both smallpox 69 
and BCG vaccination, HR = 1.75 (95% CI 0.87-3.48) compared with none of these. Vaccination 70 
below the age of one year gave similar results. 71 
Conclusions: We found no strong beneficial effect of smallpox and BCG vaccination against 72 
CMM among young adult Danes and with broad confidence intervals our data alone could be 73 
compatible with both modest preventive effects, no effects, and modest harmful effects. Our 74 
estimates do not contradict a potential modest beneficial effect of neonatal vaccination. 75 
  76 
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Introduction 77 
Evidence suggest that live vaccines protect against non-targeted diseases.(1) For instance, the 78 
Bacillus Calmette-Guérin (BCG) vaccine is used as a standard treatment in intermediate to high-79 
risk non-muscle-invasive bladder cancer,(2) even though the BCG vaccine was developed to 80 
protect against tuberculosis. During the 1970-80s, the use of the BCG vaccine  prompted great 81 
enthusiasm as an immunotherapy against cutaneous malignant melanoma (CMM).(3,4) However, 82 
in 1993, a meta-analysis of the BCG vaccine and its impact on CMM provided inconclusive 83 
results(5), and the research subsequently diminished.  84 
 85 
In 2002, it was hypothesized that the smallpox and BCG vaccines may have prophylactic effects 86 
against CMM.(6) Pfahlberg et al. noted that early timing of smallpox and BCG vaccination could 87 
be important for the immune reactions, and they suggested that this could be a reason why 88 
previous immunotherapeutic studies(3,4,7,8) failed to show an effect.(6) One mechanistic 89 
explanation was that the peptide, HERV-K-MEL, expressed by most melanomas, has 90 
homologous epitope sequences with the smallpox vaccine and the BCG vaccine, hence, cross-91 
reactivity could play a role in the protective effect.(9) It was also suggested that the vaccines 92 
replicated natural infections inducing regulatory mechanisms for the immune system.(10)  93 
 94 
We utilized the phase out period of smallpox and BCG vaccination in Denmark to investigate 95 
whether pre-school smallpox vaccination and early-school BCG vaccinations are associated with 96 
a lower risk of developing CMM among young Danes,  97 
 98 
Methods 99 
This study is a retrospective register-based case-cohort study among Danes, who attended school 100 
in Copenhagen and were followed from age 18 to 49 years. We used from all cases in the full 101 
background population and information from a sub-cohort the full background population. 102 
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Case-cohort studies are typically performed when retrieving information on exposure and 103 
confounder information is costly and timing consuming. 104 
 105 
Setting and study population  106 
In Denmark, smallpox vaccination was phased out in 1977 and phasing out the BCG vaccination 107 
was suggested in 1980, but recommendations were officially changed in 1987, whichrestricted 108 
BCG vaccination to “high risk” children.(11) Smallpox vaccination used to be compulsory(12) 109 
and children had to be smallpox vaccinated before entering school.(13) BCG vaccination was 110 
voluntary (children were tuberculosis skin tested [Mantoux or Moro test] and negative 111 
responders were referred for vaccination free of charge).(13–15) BCG was typically given during 112 
the first years of school, at the ages of 5-7.(16) Due to the difference in age at vaccination, the 113 
birth cohorts 1965-76 were affected by phase outs of both vaccines - the birth cohort 1965 had 114 
almost 100% vaccination coverage; the birth cohort 1976 had almost none (Supplementary 115 
figure 1). More information about the vaccination programme can be found in the 116 
supplementary material to Rieckmann et al. (11)  117 
 118 
The background population for this study was children born in1965-1976 and registered in the 119 
Copenhagen School Health Records Register, which comprises all children who went to school 120 
in the municipality of Copenhagen.(17) Children attended several school health examinations 121 
during their schooling, for which information about vaccination, infections anthropometrics, and 122 
other social factors were noted on paper records.(17) A case-cohort design was applied to reduce 123 
costs for digitalising information from the physical school health records for the full register. 124 
Hence, information on vaccinations and potential confounders was digitalised for all CMM cases 125 
in the background population and for a sub-cohort. The sub-cohort was selected as a 10% 126 
random sample of children within strata of sex and year of birth and for all children born the 127 
first day of every month. The digitalisation was aimed at investigating several outcomes and the 128 
stratifications were made due to specific hypotheses of sex differential effects and to account for 129 
the gradual phase out period of smallpox and BCG vaccination affecting these birth cohorts. 130 
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 131 
We excluded children who had no information about any childhood vaccines to ensure especially 132 
weak children were not included among individuals categorised as not vaccinated with the 133 
smallpox and BCG vaccines.  134 
 135 
Smallpox and BCG vaccinations and covariates 136 
The Copenhagen School Health Records Register contains information about childhood 137 
vaccines and potential confounders from the first school health examination where most parents 138 
or guardians participated.(17) The school health records were updated at each subsequent school 139 
health examination.  140 
 141 
Based on an assumed causal structure, we adjusted for sex, number of siblings (as a proxy of 142 
social class), and family social class at school entry. Contraindication against vaccination was 143 
approached by excluding children who did not have any registered childhood vaccinations on 144 
their health record. We did not have information on potentially important confounders as 145 
ethnicity and skin colour. Information on immigration (indicated by information from the school 146 
health record on birth place) and birth weight (grouped in accordance with Jensen et al.(18)) 147 
were only available for subgroups and were adjusted for in sensitivity analyses. 148 
 149 
Cutaneous malignant melanoma 150 
From 1968, all Danish citizens were assigned a unique personal identification number enabling 151 
linkage between the school health records and national health registers. The CMM cases were 152 
identified in the Danish Cancer Registry(19) with the international classification of disease codes 153 
version 10 (ICD-10), C43 and all sub-diagnoses. A validation study of the Danish cancer registry 154 
showed that the positive prediction value (PPV) and sensitivity for CMM diagnoses were 97% 155 
and 90%, respectively. The PPV varied between 87-100% for histologic subtypes of CMM 156 
(excluding “Melanoma not otherwise specified”).(20)  157 
 158 
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Statistical analyses 159 
We excluded individuals without a unique personal identification number, no health record, no 160 
vaccines received, no information about sex, family social class, and number of siblings, or who 161 
were not alive at their 18th birthday. We investigated whether individuals excluded due to missing 162 
values were different with regard to covariates from the study population. Among the included 163 
individuals, descriptive statistics between the potential confounders and BCG and/or smallpox 164 
vaccination were assessed with a prevalence ratio using a Poisson regression with robust 165 
standard errors.(21) The association between co-variables and CMM was assessed using the Cox 166 
proportional hazards model. CMM morphology and tumour location were classified according to 167 
definitions by Bay et al.(22)  168 
 169 
For the main analysis, hazard ratios (HRs) were analysed with the Cox proportional hazards 170 
model with robust variance estimation to account for the case-cohort design that would 171 
otherwise underestimate the variance.(23,24) Age was the underlying time scale and individuals 172 
entered the study at their 18th birthday (no CMM cases had occurred earlier than 18 years of age 173 
allowing us to fix baseline variables at this age). CMM cases who were not part of the sub-cohort 174 
were included in the analysis one day before their diagnosis date as described by Prentice.(23,24) 175 
This is done to ensure that cases outside the sub-cohort do not contribute to the exposure 176 
distribution among controls at earlier risk sets and thus bias the estimate by using knowledge of 177 
the exposure distribution of future cases. Individuals were followed until diagnosed with CMM 178 
or censoring (emigration, death, unknown whereabouts by the Danish authorities, or 31 179 
December 2014 [last available update of the Danish Cancer Registry]), whichever occurred first. 180 
Information on deaths and migrations was obtained from the Danish Civil Registration 181 
System.(25) All analyses were stratified by each birth year and sex due to the sampling procedure. 182 
The model assumption of proportional hazards was tested using the Schoenfeld residual test 183 
using event time, which is applicable for case-cohort designs(26). Our main analysis compared all 184 
combinations of smallpox and BCG vaccination as well as smallpox and/or BCG vaccination 185 
with not having received smallpox and BCG vaccinations. Furthermore, we analysed the 186 
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association between the age of smallpox vaccination [No smallpox vaccination, smallpox 187 
vaccination given at < 1 year, smallpox vaccination given at ≥ 1 year] and the age of BCG 188 
vaccination [No BCG vaccination, BCG vaccination given at < 1 year, BCG vaccination given at 189 
≥ 1 year] as well as of combinations of these classification. 190 
 191 
As in previous studies of the phase-out cohort,(11,27) we explored the HRs by sex and birth 192 
cohorts [1965-68, 1969-72, 1973-76]. To describe the risk of CMM across birth cohorts, we 193 
standardised the follow up time (38 years of age across all birth cohorts) and reported the 194 
proportion of the full eligible background population diagnosed with CMM before the age of 38 195 
years. In sensitivity analyses, we adjusted for immigration and birth weight in the subgroups with 196 
this information available. 197 
 198 
Results 199 
From the eligible background population of 46,239 individuals, 172 out of 188 CMM cases 200 
(91%) were analysed and 5,090 out of 6,015 individuals (85%) in the sub-cohort were analysed 201 
(Figure 1). Among the sub-cohort, 411 were censored during follow-up (127 deaths, 273 202 
emigrations, 11 unknown whereabouts by the Danish authorities). Individuals excluded due to 203 
missing information on vaccines differed compared with the study population (supplementary 204 
table 1). The median age at end of follow-up was 44 years (maximum age was 49 years).  205 
 206 
The smallpox and BCG vaccination coverage decreased over the birth years (Supplementary 207 
figure 1). Among the sub-cohort, 16.7% neither receive smallpox nor BCG vaccination; the 208 
proportion was 1.9%, 11.3% and 43.8% for the birth cohorts 1965-1968. 1969-1972, and 1973-209 
1976, respectively.  For the birth year 1965-68 (the early phase out period), the median age of 210 
smallpox vaccination was 4.3 years (The 25-75% distribution: 2.6-6.3 years) and the median age 211 
of BCG vaccination was 7.5 years (The 25-75% distribution: 6.5-8.1). Sex, number of siblings 212 
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and family social class were not associated with having smallpox and/or BCG vaccination (Table 213 
1). 214 
 215 
Tumour characteristics of the 172 CMM cases are Supplementary table 2. The risk of CMM by 216 
the age of 38 years was 0.11% for the birth cohort 1965-68, 0.22% for the birth cohort 1969-72, 217 
and 0.27% for the birth cohort 1973-76 (Supplementary table 3). Women compared with men 218 
had a higher risk of CMM (Table 1). 219 
 220 
Smallpox and/or BCG vaccination was associated with an adjusted hazard ratio (aHR) of 1.29 221 
(95% CI 0.72-2.31) for CMM compared with individuals who had not received these vaccines 222 
(Table 2).  223 
 224 
Smallpox and BCG vaccination given at less than 1 year were respectively associated with aHR 225 
of 1.57 (95% CI 0.55-4.52) and 1.51 (95% CI 0.74-3.07) for CMM compared with having neither 226 
of the vaccines (Table 3). 227 
 228 
The main estimates were similar between men and women (test of homogeneity by sex for 229 
smallpox and/or BCG vs. none of these vaccines, p-value = 0.42) (Table 2). Across the birth 230 
cohorts [1965-68, 1969-72, 1973-76], the aHR point estimate for BCG and/or smallpox for 231 
CMM increased from aHR of 0.54 (95% CI 0.13-2.28) to 1.12 (95% CI 0.48-2.66) and to 1.67 232 
(95% CI 0.07-3.70) (test for trend, p-value = 0.25) (Supplementary table 4). Adjusting for 233 
immigration (3.4% of the analysed individuals [cases and sub-cohort]) and birth weight had little 234 
impact on the estimates (Supplementary table 5 and 6). 235 
 236 
Discussion 237 
We found no protective effect of pre-school smallpox vaccination and early-school BCG 238 
vaccination against CMM among young Danes. Numbers were small, but the analysis of the 239 
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subgroup of individuals vaccinated below 1 year of age did not indicate any protective effect 240 
either – however, due to uncertainty, the estimates may be compatible with a modest protective 241 
effect 242 
 243 
Strengths and limitations 244 
Information about vaccination was collected at school health examinations and the outcome was 245 
registered prospectively using Danish registers, which has almost complete follow-up.  246 
 247 
We adjusted for measured potential confounders and restricted the cohort to individuals who 248 
received one or more childhood vaccines, thus preventing us from including children in the 249 
smallpox and BCG unvaccinated group, who would have had no chance of receiving smallpox 250 
and BCG vaccination. Eczema was a contraindication for smallpox vaccination,(11) but a meta-251 
analysis of the evidence did not suggest that eczema is associated with an increased risk of 252 
CMM.(28)  253 
 254 
The main limitation of our study relates to potential unmeasured confounding (affecting the 255 
chance of being smallpox and BCG vaccinated and the risk of developing CMM). Exposures 256 
such as UV, skin type, and number of nevi are strong predictors of CMM,(29) but are unlikely to 257 
affect vaccination status and thereby cannot be regarded as confounders. One’s country of origin, 258 
which may affect the likelihood of vaccination and affect CMM through skin type, was not 259 
adjusted for in our main analysis. However, the sensitivity analysis of a proxy of skin type, 260 
immigration based on birth place, did not affect the results of the analysis. The risk of CMM 261 
increased by each birth cohort, but since we stratified for each birth year in our analyses, our 262 
results should not be confounded by general time trends such as changes in registration and 263 
diagnostics, sunscreen use, fashion changes, sun bathing habits and vacation destinations.(29) 264 
However, our analysis across birth cohorts had a high level of uncertainty but may suggest 265 
different associations for individuals born 1965-68 and 1973-76, with a more beneficial 266 
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association of vaccination for the birth cohort born 1965-68. If true, this could be due to 267 
differential unmeasured confounding and/or differential effect modification. 268 
 269 
We did not address potential effect modification by other vaccines or major childhood infections, 270 
which has been suggested to influence the development of CMM.(30,31) CMM subtypes develop 271 
through various distinct stages of transformations.(32) If smallpox and BCG vaccination only 272 
prevents some subtypes, including all subtypes of CMM could blur the association. We had 273 
limited statistical power due to the few CMM cases in our population and the wide confidence 274 
intervals are compatible with both preventive and harmful effects of smallpox and/or BCG 275 
vaccinations on CMM at any age.  276 
Comparison with other studies 277 
The evidence suggesting that early smallpox and BCG vaccination prevents CMM comes from a 278 
multi-centre case-control study by the Febrile Infections and Melanoma (FEBIM) working group 279 
in six European countries and Israel, with 603 CMM patients and 627 controls. This study 280 
showed that being smallpox and BCG vaccinate was associated with an OR of 0.44 (95% CI 281 
0.26-0.72) for CMM.(6) Based on an hypothesis from 1986 by Rosenthal(33), neonatal BCG 282 
vaccination destroys embryonic remnants and prevents leukaemia and other cancers throughout 283 
life. Most individuals in the FEBIM study were BCG vaccinated before the age of 1 year, and 284 
interestingly data from centres in France and Italy, where BCG vaccination supposedly was given 285 
after 1 year of age, showed no beneficial association of BCG vaccination on CMM.(30) In our 286 
study, most children were BCG vaccinated at early-school ages (5-7 years). However, those few 287 
who had been BCG vaccinated below 1 year did not tend to have a lower risk of developing 288 
CMM compared with individuals who did not receive the BCG or smallpox vaccinations. 289 
 290 
Other potential reasons for a difference between the FEBIM study and ours could relate to site 291 
and population differences. It has previously been argued that an effect of BCG vaccination on 292 
childhood cancers seemed to correlate with the efficacy of BCG vaccination on tuberculosis due 293 
to differences in environmental exposure to mycobacteria.(34) However, this would be unlikely 294 
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to explain the difference in findings between our study and the FEBIM study in which most sites 295 
were also in Europe.(30) Our study followed the study population until midlife whereas the 296 
median age of the study population reported in the FEBIM study was 57 years for cases and 55 297 
years for controls(6) The FEBIM study reported the effect of both smallpox and BCG 298 
vaccination vs. none by age group. Contrary to our findings, they found that individuals younger 299 
than 50 years tended to have an even stronger effect compared with individuals 50 years or 300 
above (respective OR: 0.27 (0.09-0.80) and 0.48 (0.26-0.86)).(6)  301 
 302 
One aspect for a potential differential effect by birth cohorts favouring the oldest birth cohorts 303 
relates to revaccination. Revaccination with live vaccines, including smallpox vaccination and 304 
BCG, has been associated with additional beneficial non-specific effects, such as reducing 305 
morbidity and mortality.(35) WHO recommended re-vaccination with the smallpox vaccine 306 
every 5-10 years in non-endemic countries(36); hence, in the previous study the smallpox 307 
vaccinated individuals may have benefitted from a boosting effect which the Danish study 308 
population did not because they received their vaccination just before smallpox vaccinations 309 
were stopped. 310 
 311 
Conclusion and perspectives 312 
We did not observe a strong preventive effect on the risk of CMM by smallpox and BCG 313 
vaccination among young Danish adults. Due to a limited number of CMM cases and the 314 
corresponding uncertainty, our results are compatible with hypotheses of a modest preventive 315 
effect, a null effect or a harmful effect”. Though the smallpox vaccine is phased out globally and 316 
the BCG vaccine is phased out in many high income-countries, understanding if live vaccines 317 
confer additional protection against non-targeted diseases is of etiological interest and potentially 318 
of public health value. In addition to the live BCG and smallpox vaccines, the live yellow fewer 319 
vaccine has been suggested to reduce CMM.(37) If live vaccines alter the long-term risk for 320 
unrelated diseases, we may utilize existing and inexpensive vaccines for a much larger benefit. 321 
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We therefore urge other research groups to investigate the association in other settings and 322 
possibly address the influence of age at vaccination, re-vaccination, and of other vaccines. 323 
 324 
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Figure 1. Flow chart of the study population 451  452  453  454 
 455 
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 475 
 476 
Study population 
 
CMM Non-cases 
Total 
Outside sub-cohort 152 0 152 
Sub-cohort 20 5,070 5,090 
Total 172 5,070 5,242 
Figure 1 shows the inclusion and exclusion criteria for the study population. 477 
Abbreviations: CMM = cutaneous malignant melanoma, CSHRR = Copenhagen School Health Record Register. 478 
Across the examined birth years among the sub-cohort, 2,485 individuals (49%) had both smallpox and BCG 479 
vaccination, 372 (7%) had only smallpox vaccination, 1,371 individuals (27%) had only BCG vaccination and 862 480 
individuals (17%) had neither BCG nor smallpox vaccination. 481 
* The sum of excluded individuals is smaller than the sum of missing482 
Exclusion of 225 (4%) individuals without 
information of any childhood vaccine 
(0 CMM cases) 
Exclusion of 2 (1%) CMM cases 
without information of any childhood 
vaccine 
Exclusion of 0 CMM cases with invalid 
personal identification number 
Exclusion of 73 (1%) individuals with 
invalid personal identification number  
(0 CMM cases) 
Background population  
47,622 individuals in CSHRR born 1965 to 1976 
Eligible background population with a physical record 
46,239 individuals with a personal identification number  
Exclusion of 1,383 individuals without a personal 
identification number 
All CMM cases (188) 13% sub-cohort with a digitalized record 6,015 individuals (23 CMM cases) 
The CSHRR Register 
372,636 individuals in CSHRR born 1930 to 1989 
Exclusion of 18 (<1%) individuals with no 
school health record  
(1 CMM case) 
Exclusion of 13 (7%) CMM cases* 
without information on number of 
siblings (9) or family social class (5) 
Exclusion of 1 (<1%) CMM case with 
no school health record 
Exclusion of 458 (8%) individuals* 
without information on number of siblings 
(251) or family social class (266) 
(2 CMM cases) 
Exclusion of 0 CMM cases who 
emigrated, died, or had unknown 
whereabouts by the Danish authorities 
before their 18th birthday 
Exclusion of 151 (3%) individuals who 
died (12), emigrated (137), or had 
unknown whereabouts by the Danish 
authorities (2) before their 18th birthday  
(0 CMM cases) 
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Table 1. The association between background factors and vaccination status and the association between background factors and 
cutaneous malignant melanoma 
  
Associations with BCG and smallpox vaccination Associations with CMM 
Sub-cohort (n = 5,090) Sub-cohort and cases (n =  5,242) 
 
BCG and Smallpox vaccination at 
last school health examination  Prevalence ratio (95% CI) for vaccinated 
with either BCG and / 
or smallpox* 
All CMM Sub-cohort person years Crude hazard ratio 
(95% CI)  for 
CMM** 
None Either or n = 172 130003 
17% (n =862) 83% (n =4228)     
Sex  
 
        
Women 17% (423) 83% (2119) 1 (ref) 119 64846 1 (ref)  
Men 17% (439) 83% (2109) 0.99 (0.97-1.01) 53 65157 0.45 (0.32-0.62) 
Number of siblings       
 None 19% (148) 81% (618) 1 (ref) 25 19280 1 (ref) 
 One 16% (420) 84% (2178) 1.01 (0.98-1.04) 97 66032 1.12 (0.71-1.75) 
 Two or more 17% (294) 83% (1432) 0.98 (0.95-1.01) 50 44690 0.88 (0.54-1.43) 
Family occupational social class      
 I 24% (87) 76% (280) 1 (ref) 9 8784 1 (ref) 
 II 15% (96) 85% (530) 1.05 (1.00-1.11) 19 15375 1.26 (0.57-2.80) 
 III 16% (140) 84% (713) 1.02 (0.96-1.07) 33 21832 1.54 (0.73-3.26) 
 IV 16% (283) 84% (1509) 1.02 (0.97-1.07) 75 46351 1.64 (0.81-3.32) 
 V 16% (186) 84% (949) 1.00 (0.94-1.05) 30 29746 1.07 (0.50-2.28) 
  Unclassified 22% (70) 78% (247) 0.96 (0.90-1.03) 6 7915 0.76 (0.27-2.17) 
        
Abbreviations: BCG = Bacillus Calmette Guérin; CI = confidence interval; CMM = cutaneous malignant melanoma 
* Prevalence ratios are calculated with Poisson regression and adjusted for birth year and sex. 
** Hazard ratios are calculated using the Cox regression with age as underlying time variable, and delayed entrance at 18 years of age. The analyses were stratified for 
year of birth and sex. 
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Table 2. The association between BCG and smallpox vaccination status and cutaneous malignant melanoma, overall and stratified by sex 1 
Among all 5242 individuals (5090 in the 
sub-cohort) CMM  
Sub-cohort person 
years  Unadjusted hazard ratio* 
Adjusted hazard ratio** (95% CI) 
  n = 172 (20 in sub-cohort) 130003  (95% CI) 
Smallpox / BCG vaccinated  
 -/- 19 (3) 18986 1 (ref) 1 (ref) 
 +/- 11 (2) 10085 1.23 (0.53-2.83) 1.23 (0.53-2.86) 
 -/+ 39 (3) 31815 1.15 (0.62-2.14) 1.13 (0.61-2.09) 
 +/+ 103 (12) 69117 1.85 (0.93-3.66) 1.75 (0.87-3.48) 
 Either or 153 (17) 111017 1.34 (0.75-2.38) 1.29 (0.72-2.31) 
      
Test of proportional hazards 
(Either or vs none), p-value 
 0.94 0.17 
            
      
Women, Smallpox / BCG vaccinated   
 -/- 11 (1) 9295 1 (ref) 1 (ref) 
 +/- 8 (2) 5100 1.46 (0.50-4.24) 1.45 (0.49-4.28) 
 -/+ 26 (1) 14916 1.42 (0.63-3.19) 1.38 (0.61-3.11) 
 
+/+ 74 (6) 35535 2.17 (0.86-5.43) 2.02 (0.79-5.13) 
 Either or 108 (9) 55551 1.62 (0.75-3.51) 1.55 (0.71-3.39) 
 
   
 
 
Men, Smallpox / BCG vaccinated  
 -/- 8 (2) 9691 1 (ref) 1 (ref) 
 +/- 3 (0) 4985 0.92 (0.23-3.71) 0.93 (0.23-3.77) 
 -/+ 13 (2) 16899 0.82 (0.31-2.13) 0.81 (0.31-2.12) 
 
+/+ 29 (6) 33582 1.45 (0.53-3.91) 1.40 (0.52-3.81) 
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 Either or 53 (10) 55466 0.98 (0.42-2.29) 0.96 (0.41-2.27) 
    
Test of interaction for “Either or” vs none by sex, p-value  0.39 0.42 
          
Abbreviations: BCG = Bacillus Calmette Guérin; CI = Confidence interval; CMM = cutaneous malignant melanoma 2 
* Hazard ratios are calculated using a Cox regression with age as underlying time variable, delayed entrance at age 18 years, and stratified for sex and year of birth. 3 
** Hazard ratios are calculated using a Cox regression with age as underlying time variable, delayed entrance at age 18 years, adjusted for family social class and number of siblings and 4 
stratified for sex and year of birth. 5 
 6 
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 7 
Table 3. The association between BCG and smallpox vaccination < 1 year of age and cutaneous malignant melanoma 8 
Among all 5242 individuals (5090 in the 
sub-cohort) 
Malignant 
melanoma  
Sub-cohort 
person 
years  Unadjusted hazard 
ratio* 
(95% CI) 
Adjusted hazard 
ratio** (95% CI) 
  n = 172 (20 in sub-cohort) 130003 
  
Age at smallpox vaccination   
 No smallpox vaccination 58 (6) 50801 1 (ref) 1 (ref) 
 Smallpox vaccination < 1 year 4 (0) 2367 1.68 (0.59-4.82) 1.57 (0.55-4.52) 
 Smallpox vaccination ≥ 1 year 110 (14) 76835 1.55 (0.98-2.44) 1.47 (0.92-2.33) 
      
      
Age at BCG vaccination     
 No BCG vaccination 30 (5) 29070 1 (ref) 1 (ref) 
 BCG vaccination < 1 year 12 (0) 7160 1.65 (0.84-3.34) 1.51 (0.74-3.07) 
 BCG vaccination ≥ 1 year 130 (15) 93777 1.33 (0.86-2.07) 1.24 (0.80-1.94) 
      
      
    
Unadjusted hazard 
ratio* 
(95% CI) 
Adjusted hazard 
ratio*** (95% CI) 
Age at smallpox and BCG vaccination analysed 
together 
   
 None 19 (3) 18986 1 (ref) 1 (ref) 
 Both smallpox and BCG vaccination < 1 year 2 (0) 587 3.76 (0.79-17.94) 3.70 (0.77-17.90) 
 Either smallpox or BCG vaccination < 
1 year 12 (0) 8350 1.41 (0.63-3.14) 1.36 (0.60-3.07) 
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 Remaining individuals with either a 
smallpox or BCG vaccination ≥ 1 year 139 (17) 103081 1.33 (0.74-2.37) 1.28 (0.71-2.29) 
      
There were 178 individuals with smallpox vaccination for whom we did not have their age at the vaccination registered in the school health records. They were classified with smallpox 9 
vaccination at >= 1 year. 10 
There were 109 individuals with BCG vaccination for whom we did not have their age at vaccination registered in the school health records. They were classified with BCG vaccination at 11 
>= 1 year. 12 
Abbreviations: BCG = Bacillus Calmette-Guérin; CI = Confidence interval; CMM = cutaneous malignant melanoma 13 
* Hazard ratios are calculated using a Cox regression with age as underlying time variable, delayed entrance at age 18 years, and stratified for sex and year of birth. 14 
** Hazard ratios are calculated using a Cox regression with age as underlying time variable, delayed entrance at age 18 years, adjusted for family social class and number of siblings, the 15 
respective age of the other vaccine (smallpox/BCG vaccination) and stratified for sex and year of birth. 16 
*** Hazard ratios are calculated using a Cox regression with age as underlying time variable, delayed entrance at age 18 years, adjusted for family social class and number of siblings and 17 
stratified for sex and year of birth. 18 
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